Cholesterol: Its regulation and role in central nervous system disorders

Cholesterol

Volumn 2012, Issue , 2012, Pages

  Orth, Matthias ^a   Bellosta, Stefano ^b  

^a Vinzenz von Paul Kliniken GGmbH   (Germany)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 7 DEHYDROCHOLESTEROL; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ATORVASTATIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CERIVASTATIN; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTEROL; CLUSTERIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PITAVASTATIN; PRAVASTATIN; PROTEIN PATCHED 1; ROSUVASTATIN; SIMVASTATIN; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMNESIA; BLOOD BRAIN BARRIER; CELL SPECIFICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; COGNITIVE DEFECT; DEMENTIA; DISTRESS SYNDROME; DRUG EFFECT; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; HYPERCHOLESTEROLEMIA; LIPOPHILICITY; MEMORY DISORDER; NIEMANN PICK DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SMITH LEMLI OPITZ SYNDROME;

EID: 84869020804     PISSN: 20901283     EISSN: 20901291     Source Type: Journal    
DOI: 10.1155/2012/292598     Document Type: Review

References (233)

1. Dietschy J. M., Turley S. D., Cholesterol metabolism in the brain. Current Opinion in Lipidology 2001 12 2 105 112 2-s2.0-0035083555 10.1097/00041433-200104000-00003 (Pubitemid 32242918)
2. Björkhem I., Meaney S., Fogelman A. M., Brain cholesterol: long secret life behind a barrier. Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 5 806 815 2-s2.0-2442557294 10.1161/01.ATV.0000120374.59826.1b (Pubitemid 38620856)
3. Korade Z., Kenworthy A. K., Lipid rafts, cholesterol, and the brain. Neuropharmacology 2008 55 8 1265 1273 2-s2.0-56249124005 10.1016/j.neuropharm. 2008.02.019
4. Fester L., Zhou L., Bütow A., Huber C., Von Lossow R., Prange-Kiel J., Jarry H., Rune G. M., Cholesterol-promoted synaptogenesis requires the conversion of cholesterol to estradiol in the hippocampus. Hippocampus 2009 19 8 692 705 2-s2.0-67349113118 10.1002/hipo.20548
5. Goritz C., Mauch D. H., Pfrieger F. W., Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron. Molecular and Cellular Neuroscience 2005 29 2 190 201 2-s2.0-19444372396 10.1016/j.mcn.2005.02.006 (Pubitemid 40725610)
6. Posse de Chaves E. I., Rusinol A. E., Vance D. E., Campenot R. B., Vance J. E., Role of lipoproteins in the delivery of lipids to axons during axonal regeneration. The Journal of Biological Chemistry 1997 272 49 30766 30773 2-s2.0-0030661651 10.1074/jbc.272.49.30766 (Pubitemid 27527513)
7. Koudinov A. R., Koudinova N. V., Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. Journal of the Neurological Sciences 2005 229-230 233 240 2-s2.0-14844321855 10.1016/j.jns.2004.11.036 (Pubitemid 40341588)
8. Herz J., Bock H. H., Lipoprotein receptors in the nervous system. Annual Review of Biochemistry 2002 71 405 434 2-s2.0-0035997373 10.1146/annurev. biochem.71.110601.135342 (Pubitemid 34800226)
9. DeBarber A. E., Eroglu Y., Merkens L. S., Smith-Lemli-Opitz syndrome. Expert Reviews in Molecular Medicine 2011 13 e24
10. Madra M., Sturley S. L., Niemann-Pick type C pathogenesis and treatment: from statins to sugars. Clinical Lipidology 2010 5 3 387 395 2-s2.0-77953868426 10.2217/clp.10.19
11. Block R. C., Dorsey E. R., Beck C. A., Brenna J., Shoulson I., Altered cholesterol and fatty acid metabolism in Huntington disease. Journal of Clinical Lipidology 2010 4 1 17 23 2-s2.0-75849142894 10.1016/j.jacl.2009.11.003
12. Di Paolo G., Kim T. W., Linking lipids to Alzheimer's disease: Cholesterol and beyond. Nature Reviews Neuroscience 2011 12 5 284 296 2-s2.0-79955051063 10.1038/nrn3012
13. Herz J., Apolipoprotein E receptors in the nervous system. Current Opinion in Lipidology 2009 20 3 190 196
14. Pitas R. E., Boyles J. K., Lee S. H., Hui D., Weisgraber K. H., Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. The Journal of Biological Chemistry 1987 262 29 14352 14360 2-s2.0-0023280054 (Pubitemid 17152101)
15. Brown M. S., Goldstein J. L., Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. Journal of Clinical Investigation 1983 72 3 743 747 2-s2.0-0021076682 (Pubitemid 14211383)
16. Couerbe J. P., Du cerveau, considéré sous le point du vue chimique et physiologique. Annales De Chimie Ed De Physique 1834 56 160 193
17. Waterham H. R., Defects of cholesterol biosynthesis. FEBS Letters 2006 580 23 5442 5449 2-s2.0-33749256472 10.1016/j.febslet.2006.07.027 (Pubitemid 44479759)
18. Bellosta S., Ferri N., Arnaboldi L., Bernini F., Paoletti R., Corsini A., Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 2000 23 supplement 2 B72 B78 2-s2.0-0034115496 (Pubitemid 30185781)
19. Bae S. H., Lee J. N., Fitzky B. U., Cholesterol biosynthesis from lanosterol. Molecular cloning, tissue distribution, expression, chromosomal localization, and regulation of rat 7-dehydrocholesterol reductase, a Smith-Lemli-Opitz syndrome-related protein. The Journal of Biological Chemistry 1999 274 21 14624 14631 2-s2.0-0033618345
20. Gaylor J. L., Membrane-bound enzymes of cholesterol synthesis from lanosterol. Biochemical and Biophysical Research Communications 2002 292 5 1139 1146 2-s2.0-0036085695 10.1006/bbrc.2001.2008 (Pubitemid 34681085)
21. Goldstein J. L., Brown M. S., Regulation of the mevalonate pathway. Nature 1990 343 6257 425 430 2-s2.0-0025120211 10.1038/343425a0 (Pubitemid 20065229)
22. Snipes G. J., Suter U., Cholesterol and myelin. Sub-Cellular Biochemistry 1997 28 173 204 2-s2.0-0030628019
23. Morell P., Jurevics H., Origin of cholesterol in myelin. Neurochemical Research 1996 21 4 463 470 2-s2.0-0029942903 10.1007/BF02527711 (Pubitemid 26159264)
24. Martin M., Dotti C. G., Ledesma M. D., Brain cholesterol in normal and pathological aging. Biochimica et Biophysica Acta 2010 1801 8 934 944 2-s2.0-77953269718 10.1016/j.bbalip.2010.03.011
25. Andersson M., Elmberger P. G., Edlund C., Kristensson K., Dallner G., Rates of cholesterol, ubiquinone, dolichol and dolichyl-P biosynthesis in rat brain slices. FEBS Letters 1990 269 1 15 18 2-s2.0-0025148205 10.1016/0014-5793(90)81107-Y (Pubitemid 20245305)
26. Björkhem I., Heverin M., Leoni V., Meaney S., Diczfalusy U., Oxysterols and Alzheimer's disease. Acta Neurologica Scandinavica 2006 114 185 43 49 2-s2.0-33745761211 10.1111/j.1600-0404.2006.00684.x (Pubitemid 44015224)
27. Dietschy J. M., Turley S. D., Cholesterol metabolism in the central nervous system during early development and in the mature animal. Journal of Lipid Research 2004 45 8 1375 1397 2-s2.0-3543104951 10.1194/jlr.R400004-JLR200 (Pubitemid 39022664)
28. Waelsch H., Sperry W., Stoyanoff V. A., A study of the synthesis and deposition of lipids in brain and other tissues with deuterium as an indicator. The Journal of Biological Chemistry 1940 135 291 296
29. Bloch K., Berg B. N., Rittenberg D., The biological conversion of cholesterol to cholic acid. The Journal of Biological Chemistry 1943 149 511 517
30. Jurevics H., Morell P., Cholesterol for synthesis of myelin is made locally, not imported into brain. Journal of Neurochemistry 1995 64 2 895 901 2-s2.0-0028801536
31. Turley S. D., Burns D. K., Rosenfeld C. R., Dietschy J. M., Brain does not utilize low density lipoprotein-cholesterol during fetal and neonatal development in the sheep. Journal of Lipid Research 1996 37 9 1953 1961 2-s2.0-0029795699 (Pubitemid 26307676)
32. Dietschy J. M., Turley S. D., Control of cholesterol turnover in the mouse. The Journal of Biological Chemistry 2002 277 6 3801 3804 2-s2.0-0037040184 10.1074/jbc.R100057200 (Pubitemid 34968627)
33. Vanmierlo T., Weingärtner O., Van der Pol S., Dietary intake of plant sterols stably increases plant sterol levels in the murine brain. The Journal of Lipid Research 2012 53 4 726 735
34. Chobanian A. V., Hollander W., Body cholesterol metabolism in man. I. The equilibration of serum and tissue cholesterol. The Journal of clinical investigation 1962 41 1732 1737 2-s2.0-0001762002
35. Lütjohann D., Stroick M., Bertsch T., Kühl S., Lindenthal B., Thelen K., Andersson U., Björkhem I., Von Bergmann K., Fassbender K., High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 2004 69 6 431 438 2-s2.0-3042640736 10.1016/j.steroids.2004.03.012 (Pubitemid 38829339)
36. Meaney S., Lütjohann D., Diczfalusy U., Björkhem I., Formation of oxysterols from different pools of cholesterol as studied by stable isotope technique: cerebral origin of most circulating 24S-hydroxycholesterol in rats, but not in mice. Biochimica et Biophysica Acta 2000 1486 2-3 293 298 2-s2.0-0343962646 10.1016/S1388-1981(00)00070-6 (Pubitemid 30618869)
37. Herz J., Farese R. V. Jr., The LDL receptor gene family, apolipoprotein B and cholesterol in embryonic development. Journal of Nutrition 1999 129 supplement 2S 2-s2.0-0032908113
38. Jurevics H. A., Kidwai F. Z., Morell P., Sources of cholesterol during development of the rat fetus and fetal organs. Journal of Lipid Research 1997 38 4 723 733 2-s2.0-0030957561 (Pubitemid 27194923)
39. Muse E. D., Jurevics H., Toews A. D., Matsushima G. K., Morell P., Parameters related to lipid metabolism as markers of myelination in mouse brain. Journal of Neurochemistry 2001 76 1 77 86 2-s2.0-0035158236 10.1046/j.1471-4159.2001.00015.x (Pubitemid 32044370)
40. Saher G., Brügger B., Lappe-Siefke C., Möbius W., Tozawa R. I., Wehr M. C., Wieland F., Ishibashi S., Nave K. A., High cholesterol level is essential for myelin membrane growth. Nature Neuroscience 2005 8 4 468 475 2-s2.0-20044370505 10.1038/nn1426 (Pubitemid 41007564)
41. Ko M., Zou K., Minagawa H., Yu W., Gong J. S., Yanagisawa K., Michikawa M., Cholesterol-mediated neurite outgrowth is differently regulated between cortical and hippocampal neurons. The Journal of Biological Chemistry 2005 280 52 42759 42765 2-s2.0-30044432496 10.1074/jbc.M509164200 (Pubitemid 43049237)
42. Pooler A. M., Xi S. C., Wurtman R. J., The 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor pravastatin enhances neurite outgrowth in hippocampal neurons. Journal of Neurochemistry 2006 97 3 716 723 2-s2.0-33645854917 10.1111/j.1471-4159.2006.03763.x
43. Saito M., Benson E. P., Saito M., Rosenberg A., Metabolism of cholesterol and triacylglycerol in cultured chick neuronal cells, glial cells, and fibroblasts: accumulation of esterified cholesterol in serum-free culture. Journal of Neuroscience Research 1987 18 2 319 325 2-s2.0-0023550598 (Pubitemid 18016460)
44. Suzuki S., Kiyosue K., Hazama S., Ogura A., Kashihara M., Hara T., Koshimizu H., Kojima M., Brain-derived neurotrophic factor regulates cholesterol metabolism for synapse development. Journal of Neuroscience 2007 27 24 6417 6427 2-s2.0-34250307168 10.1523/JNEUROSCI.0690-07.2007 (Pubitemid 46920374)
45. Fünfschilling U., Saher G., Xiao L., Möbius W., Nave K. A., Survival of adult neurons lacking cholesterol synthesis in vivo. BMC Neuroscience 2007 8 1 2-s2.0-33846565903 10.1186/1471-2202-8-1 (Pubitemid 46178875)
46. Pfrieger F. W., Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? BioEssays 2003 25 1 72 78 2-s2.0-0037230328 10.1002/bies.10195 (Pubitemid 36093328)
47. Korade Z., Mi Z., Portugal C., Schor N. F., Expression and p75 neurotrophin receptor dependence of cholesterol synthetic enzymes in adult mouse brain. Neurobiology of Aging 2007 28 10 1522 1531 2-s2.0-34547726261 10.1016/j.neurobiolaging.2006.06.026 (Pubitemid 47238533)
48. Ong W. Y., Kim J. H., He X., Chen P., Farooqui A. A., Jenner A. M., Changes in brain cholesterol metabolome after excitotoxicity. Molecular Neurobiology 2010 41 2-3 299 313 2-s2.0-77953290487 10.1007/s12035-010-8099-3
49. Zhang Y., Appelkvist E. L., Kristensson K., Dallner G., The lipid compositions of different regions of rat brain during development and aging. Neurobiology of Aging 1996 17 6 869 875 2-s2.0-0030294860 10.1016/S0197-4580(96) 00076-0 (Pubitemid 27022740)
50. Quan G., Xie C., Dietschy J. M., Turley S. D., Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. Developmental Brain Research 2003 146 1-2 87 98 2-s2.0-0344011516 10.1016/j.devbrainres.2003.09.015 (Pubitemid 37474113)
51. Numakawa T., Suzuki S., Kumamaru E., Adachi N., Richards M., Kunugi H., BDNF function and intracellular signaling in neurons. Histology and Histopathology 2010 25 2 237 258 2-s2.0-74449091832
52. Yu H., Patel S. B., Recent insights into the Smith-Lemli-Opitz syndrome. Clinical Genetics 2005 68 5 383 391 2-s2.0-27544490417 10.1111/j.1399-0004.2005. 00515.x (Pubitemid 41535963)
53. Jira P. E., Waterham H. R., Wanders R. J. A., Smeitink J. A. M., Sengers R. C. A., Wevers R. A., Smith-Lemli-Opitz syndrome and the DHCR7 gene. Annals of Human Genetics 2003 67 part 3 269 280 2-s2.0-0344258576 10.1046/j.1469-1809. 2003.00034.x (Pubitemid 38312833)
54. Fitzky B. U., Moebius F. F., Asaoka H., Waage-Baudet H., Xu L., Xu G., Maeda N., Kluckman K., Hiller S., Yu H., Batta A. K., Shefer S., Chen T., Salen G., Sulik K., Simoni R. D., Ness G. C., Glossmann H., Patel S. B., Tint G. S., 7-Dehydrocholesterol-dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/RSH syndrome. Journal of Clinical Investigation 2001 108 6 905 915 2-s2.0-0034829757 10.1172/JCI200112103 (Pubitemid 32880299)
55. Xu X., Bittman R., Duportail G., Heissler D., Vilcheze C., London E., Effect of the structure of natural sterols and sphingolipids on the formation of ordered sphingolipid/sterol domains (rafts). Comparison of cholesterol to plant, fungal, and disease-associated sterols and comparison of sphingomyelin, cerebrosides, and ceramide. The Journal of Biological Chemistry 2001 276 36 33540 33546 2-s2.0-0035823586 10.1074/jbc.M104776200
56. Vainio S., Jansen M., Koivusalo M., Róg T., Karttunen M., Vattulainen I., Ikonen E., Significance of sterol structural specificity: desmosterol cannot replace cholesterol in lipid rafts. The Journal of Biological Chemistry 2006 281 1 348 355 2-s2.0-33644871685 10.1074/jbc.M509530200 (Pubitemid 43671195)
57. Ollila S., Hyvönen M. T., Vattulainen I., Polyunsaturation in lipid membranes: dynamic properties and lateral pressure profiles. Journal of Physical Chemistry B 2007 111 12 3139 3150 2-s2.0-34147092095 10.1021/jp065424f (Pubitemid 46573461)
58. Singh P., Paila Y. D., Chattopadhyay A., Differential effects of cholesterol and 7-dehydrocholesterol on the ligand binding activity of the hippocampal serotonin1A receptor: implications in SLOS. Biochemical and Biophysical Research Communications 2007 358 2 495 499 2-s2.0-34248591321 10.1016/j.bbrc.2007.04.135 (Pubitemid 46755732)
59. Leoni V., Mariotti C., Nanetti L., Salvatore E., Squitieri F., Bentivoglio A. R., di Poggio M. B., Piacentini S., Monza D., Valenza M., Cattaneo E., Di Donato S., Whole body cholesterol metabolism is impaired in Huntington's disease. Neuroscience Letters 2011 494 3 245 249 2-s2.0-79958710607 10.1016/j.neulet.2011.04.075
60. Sipione S., Rigamonti D., Valenza M., Zuccato C., Conti L., Pritchard J., Kooperberg C., Olson J. M., Cattaneo E., Early transcriptional profiles in huntingtin-induced striatal cells by microarray analyses. Human Molecular Genetics 2002 11 17 1953 1965 2-s2.0-0037101839 (Pubitemid 34919271)
61. Valenza M., Carroll J. B., Leoni V., Bertram L. N., Björkhem I., Singaraja R. R., Di Donato S., Lutjohann D., Hayden M. R., Cattaneo E., Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Human Molecular Genetics 2007 16 18 2187 2198 2-s2.0-34548379904 10.1093/hmg/ddm170 (Pubitemid 47354901)
62. Harris F. M., Tesseur I., Brecht W. J., Xu Q., Mullendorff K., Chang S., Wyss-Coray T., Mahley R. W., Huang Y., Astroglial regulation of apolipoprotein E expression in neuronal cells: implications for Alzheimer's disease. The Journal of Biological Chemistry 2004 279 5 3862 3868 2-s2.0-0942287189 10.1074/jbc.M309475200 (Pubitemid 38140631)
63. Xu Q., Bernardo A., Walker D., Kanegawa T., Mahley R. W., Huang Y., Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. Journal of Neuroscience 2006 26 19 4985 4994 2-s2.0-33646911081 10.1523/JNEUROSCI.5476-05. 2006 (Pubitemid 44315280)
64. Björkhem I., Lütjohann D., Diczfalusy U., Ståhle L., Ahlborg G., Wahren J., Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. Journal of Lipid Research 1998 39 8 1594 1600 2-s2.0-0031848338 (Pubitemid 28377923)
65. Heverin M., Meaney S., Lütjohann D., Diczfalusy U., Wahren J., Björkhem I., Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. Journal of Lipid Research 2005 46 5 1047 1052 2-s2.0-23744498856 10.1194/jlr.M500024-JLR200
66. Meaney S., Bodin K., Diczfalusy U., Björkhem I., On the rate of translocation in vitro and kinetics in vivo of the major oxysterols in human circulation: critical importance of the position of the oxygen function. Journal of Lipid Research 2002 43 12 2130 2135 2-s2.0-0036916491 10.1194/jlr.M200293- JLR200 (Pubitemid 35471081)
67. Lütjohann D., Breuer O., Ahlborg G., Nennesmo I., Sidén Å.., Diczfalusy U., Björkhem I., Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proceedings of the National Academy of Sciences of the United States of America 1996 93 18 9799 9804 2-s2.0-0029835410 10.1073/pnas.93.18.9799 (Pubitemid 26296689)
68. Björkhem I., Cedazo-Minguez A., Leoni V., Meaney S., Oxysterols and neurodegenerative diseases. Molecular Aspects of Medicine 2009 30 3 171 179 2-s2.0-67349094556 10.1016/j.mam.2009.02.001
69. Björkhem I., Diczfalusy U., Oxysterols: friends, foes, or just fellow passengers? Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 5 734 742 2-s2.0-0036096897 10.1161/01.ATV.0000013312.32196.49 (Pubitemid 34517783)
70. Senn H. J., Orth M., Fitzke E., Koster W., Wieland H., Gerok W., Human serum gangliosides in hypercholesterolemia, before and after extracorporeal elimination of LDL. Atherosclerosis 1992 94 2-3 109 117 2-s2.0-0026715979 10.1016/0021-9150(92)90235-9
71. Senn H. J., Orth M., Fitzke E., Wieland H., Gerok W., Ganglioside in normal human serum. Concentration, pattern and transport by lipoproteins. European Journal of Biochemistry 1989 181 3 657 662 2-s2.0-0024474674 (Pubitemid 19146930)
72. Leoni V., Masterman T., Patel P., Meaney S., Diczfalusy U., Björkhem I., Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers. Journal of Lipid Research 2003 44 4 793 799 2-s2.0-0141700567 10.1194/jlr.M200434-JLR200 (Pubitemid 37279681)
73. Lathe R., Steroid and sterol 7-hydroxylation: ancient pathways. Steroids 2002 67 12 967 977 2-s2.0-0036887723 10.1016/S0039-128X(02)00044-2 (Pubitemid 35175464)
74. Xie C., Burns D. K., Turley S. D., Dietschy J. M., Cholesterol is sequestered in the brains of mice with Niemann-Pick Type C disease but turnover is increased. Journal of Neuropathology and Experimental Neurology 2000 59 12 1106 1117 2-s2.0-0034534808 (Pubitemid 32006313)
75. Wilson J. D., The measurement of the exchangeable pools of cholesterol in the baboon. Journal of Clinical Investigation 1970 49 4 655 665 2-s2.0-0014770106
76. Lund E. G., Guileyardo J. M., Russell D. W., cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proceedings of the National Academy of Sciences of the United States of America 1999 96 13 7238 7243 2-s2.0-0033594903 10.1073/pnas.96.13.7238 (Pubitemid 29299645)
77. Bretillon L., Diczfalusy U., Björkhem I., Maire M. A., Martine L., Joffre C., Acar N., Bron A., Creuzot-Garcher C., Cholesterol-24S-hydroxylase (CYP46A1) is specifically expressed in neurons of the neural retina. Current Eye Research 2007 32 4 361 366 2-s2.0-33947324152 10.1080/02713680701231857 (Pubitemid 46633860)
78. Lund E. G., Xie C., Kotti T., Turley S. D., Dietschy J. M., Russell D. W., Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. The Journal of Biological Chemistry 2003 278 25 22980 22988 2-s2.0-0038265008 10.1074/jbc.M303415200 (Pubitemid 36830363)
79. Janowski B. A., Willy P. J., Devi T. R., Falck J. R., Mangelsdorf D. J., An oxysterol signalling pathway mediated by the nuclear receptor LXR α Nature 1996 383 6602 728 731 2-s2.0-0029805887 10.1038/383728a0 (Pubitemid 26360651)
80. Lehmann J. M., Kliewer S. A., Moore L. B., Smith-Oliver T. A., Oliver B. B., Su J. L., Sundseth S. S., Winegar D. A., Blanchard D. E., Spencer T. A., Willson T. M., Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. The Journal of Biological Chemistry 1997 272 6 3137 3140 2-s2.0-14444285707 10.1074/jbc.272.6.3137 (Pubitemid 27066798)
81. Brown J., Theisler C., Silberman S., Magnuson D., Gottardi-Littell N., Lee J. M., Yager D., Crowley J., Sambamurti K., Rahman M. M., Reiss A. B., Eckman C. B., Wolozin B., Differential expression of cholesterol hydroxylases in Alzheimer's disease. The Journal of Biological Chemistry 2004 279 33 34674 34681 2-s2.0-4544255297 10.1074/jbc.M402324200 (Pubitemid 39318097)
82. Whitney K. D., Watson M. A., Collins J. L., Benson W. G., Stone T. M., Numerick M. J., Tippin T. K., Wilson J. G., Winegar D. A., Kliewer S. A., Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Molecular Endocrinology 2002 16 6 1378 1385 2-s2.0-0035989261 10.1210/me.16.6.1378 (Pubitemid 34621083)
83. Björkhem I., Do oxysterols control cholesterol homeostasis? Journal of Clinical Investigation 2002 110 6 725 730 2-s2.0-0036736781 10.1172/JCI200216388
84. Wang L., Schuster G. U., Hultenby K., Zhang Q., Andersson S., Gustafsson J. Å., Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proceedings of the National Academy of Sciences of the United States of America 2002 99 21 13878 13883 2-s2.0-0037108819 10.1073/pnas.172510899 (Pubitemid 35215474)
85. Hall M. G., Quignodon L., Desvergne B., Peroxisome proliferator-activated receptor β / δ in the brain: facts and hypothesis. PPAR Research 2008 2008 10 2-s2.0-55949111070 10.1155/2008/780452 780452
86. Yue L., Mazzone T., Peroxisome proliferator-activated receptor γ stimulation of adipocyte ApoE gene transcription mediated by the liver receptor X pathway. The Journal of Biological Chemistry 2009 284 16 10453 10461 2-s2.0-67449107799 10.1074/jbc.M808482200
87. Chawta A., Repa J. J., Evans R. M., Mangelsdorf D. J., Nuclear receptors and lipid physiology: opening the x-files. Science 2001 294 5548 1866 1870 2-s2.0-0035976638 10.1126/science.294.5548.1866 (Pubitemid 33101573)
88. Dehouck B., Dehouck M. P., Fruchart J. C., Cecchelli R., Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes. Journal of Cell Biology 1994 126 2 465 473 2-s2.0-0028342454 10.1083/jcb.126.2.465 (Pubitemid 24226262)
89. Zambón D., Quintana M., Mata P., Alonso R., Benavent J., Cruz-Sánchez F., Gich J., Pocoví M., Civeira F., Capurro S., Bachman D., Sambamurti K., Nicholas J., Pappolla M. A., Higher incidence of mild cognitive impairment in familial hypercholesterolemia. The American journal of medicine 2010 123 3 267 274 2-s2.0-77950486318
90. Vega G. L., Weiner M. F., Lipton A. M., Von Bergmann K., Lütjohann D., Moore C., Svetlik D., Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Archives of Neurology 2003 60 4 510 515 2-s2.0-0037388527 10.1001/archneur.60.4.510 (Pubitemid 36427965)
91. Fassbender K., Stroick M., Bertsch T., Ragoschke A., Kuehl S., Walter S., Walter J., Brechtel K., Muehlhauser F., Von Bergmann K., Lütjohann D., Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 2002 59 8 1257 1258 2-s2.0-0037159224 (Pubitemid 35192402)
92. Simons M., Schwärzler F., Lütjohann D., Von Bergmann K., Beyreuther K., Dichgans J., Wormstall H., Hartmann T., Schulz J. B., Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Annals of Neurology 2002 52 3 346 350 2-s2.0-0036714243 10.1002/ana.10292 (Pubitemid 35001502)
93. Locatelli S., Lütjohann D., Schmidt H. H. J., Otto C., Beisiegel U., Von Bergmann K., Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Archives of Neurology 2002 59 2 213 216 2-s2.0-0036128358 (Pubitemid 34240936)
94. Willnow T. E., Hilpert J., Armstrong S. A., Rohlmann A., Hammer R. E., Burns D. K., Herz J., Defective forebrain development in mice lacking gp330/megalin. Proceedings of the National Academy of Sciences of the United States of America 1996 93 16 8460 8464 2-s2.0-0029775625 10.1073/pnas.93.16.8460 (Pubitemid 26269580)
95. Roessler E., Belloni E., Gaudenz K., Jay P., Berta P., Scherer S. W., Tsui L. C., Muenke M., Mutations in the human Sonic Hedgehog gene cause holoprosencephaly. Nature genetics 1996 14 3 357 360 2-s2.0-0030294408
96. Lorusso P. M., Jimeno A., Dy G., Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clinical Cancer Research 2011 17 17 5774 5782
97. Ingham P. W., Nakano Y., Seger C., Mechanisms and functions of Hedgehog signalling across the metazoa. Nature Reviews Genetics 2011 12 6 393 406 2-s2.0-79956308325 10.1038/nrg2984
98. Alvarez J. I., Dodelet-Devillers A., Kebir H., The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science 2011 334 6063 1727 1731
99. Herz J., Willnow T. E., Farese R. E., Cholesterol, hedgehog and embryogenesis. Nature Genetics 1997 15 2 123 124 2-s2.0-0031053389 10.1038/ng0297-123 (Pubitemid 27061629)
100. Baardman M. E., Erwich J. J., Berger R. M., The origin of fetal sterols in second-trimester amniotic fluid: endogenous synthesis or maternal-fetal transport? American Journal of Obstetrics and Gynecology 2012 207 3 202.e19 202.e25
101. Woollett L. A., The origins and roles of cholesterol and fatty acids in the fetus. Current Opinion in Lipidology 2001 12 3 305 312 2-s2.0-0034965078 10.1097/00041433-200106000-00010 (Pubitemid 32536687)
102. Véniant M. M., Kim E., McCormick S., Borén J., Nielsen L. B., Raabe M., Young S. G., Insights into apolipoprotein B biology from transgenic and gene-targeted mice. Journal of Nutrition 1999 129 supplement 2S 451S 455S 2-s2.0-0345003924 (Pubitemid 29069644)
103. Raabe M., Flynn L. M., Zlot C. H., Wong J. S., Véniant M. M., Hamilton R. L., Young S. G., Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. Proceedings of the National Academy of Sciences of the United States of America 1998 95 15 8686 8691 2-s2.0-0032555195 10.1073/pnas.95.15.8686 (Pubitemid 28350549)
104. Cholesterol Treatment Trialists C, Baigent C., Blackwell L., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. The Lancet 2010 376 9753 1670 1681
105. Shepardson N. E., Shankar G. M., Selkoe D. J., Cholesterol level and statin use in Alzheimer disease: II. review of human trials and recommendations. Archives of Neurology 2011 68 11 1385 1392
106. Willey J. Z., Elkind M. S. V., 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Archives of Neurology 2010 67 9 1062 1067 2-s2.0-77957038341 10.1001/archneurol.2010.199
107. Thelen K. M., Rentsch K. M., Gutteck U., Heverin M., Olin M., Andersson U., Von Eckardstein A., Björkhem I., Lütjohann D., Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. Journal of Pharmacology and Experimental Therapeutics 2006 316 3 1146 1152 2-s2.0-33644781781 10.1124/jpet.105.094136 (Pubitemid 43345288)
108. Sparks D. L., Connor D. J., Browne P. J., Lopez J. E., Sabbagh M. N., HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. Journal of Nutrition, Health and Aging 2002 6 5 324 331 2-s2.0-0036964776 (Pubitemid 36118981)
109. Serbanescu I., Ryan M. A., Shukla R., Cortez M. A., Snead O. C., Cunnane S. C., Lovastatin exacerbates atypical absence seizures with only minimal effects on brain sterols. Journal of Lipid Research 2004 45 11 2038 2043 2-s2.0-21644473600 10.1194/jlr.M400097-JLR200 (Pubitemid 40990898)
110. Maier O., De Jonge J., Nomden A., Hoekstra D., Baron W., Lovastatin induces the formation of abnormal myelin-like membrane sheets in primary oligodendrocytes. GLIA 2009 57 4 402 413 2-s2.0-66149089362 10.1002/glia.20769
111. McGuinness B., O'Hare J., Craig D., Bullock R., Malouf R., Passmore P., Cochrane review on 'statins for the treatment of dementia' International Journal of Geriatric Psychiatry. In press 10.1002/gps.3797
112. Yamamoto T., Davis C. G., Brown M. S., The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 1984 39 1 27 38 2-s2.0-0021742599 (Pubitemid 15218222)
113. Banks W. A., Erickson M. A., The blood-brain barrier and immune function and dysfunction. Neurobiology of Disease 2010 37 1 26 32 2-s2.0-70449529633 10.1016/j.nbd.2009.07.031
114. Beziaud T., Ru Chen X., El Shafey N., Simvastatin in traumatic brain injury: effect on brain edema mechanisms. Crit Care Med 2011 39 10 2300 2307
115. Guillot F., Misslin P., Lemaire M., Comparison of fluvastatin and lovastatin blood-brain barrier transfer using in vitro and in vivo methods. Journal of Cardiovascular Pharmacology 1993 21 2 339 346 2-s2.0-0027464373 (Pubitemid 23027613)
116. Saheki A., Terasaki T., Tamai I., Tsuji A., In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharmaceutical Research 1994 11 2 305 311 2-s2.0-0028281788 10.1023/A:1018975928974 (Pubitemid 24076229)
117. Nezasa K. I., Higaki K., Matsumura T., Inazawa K., Hasegawa H., Nakano M., Koike M., Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metabolism and Disposition 2002 30 11 1158 1163 2-s2.0-0036840329 10.1124/dmd.30.11.1158 (Pubitemid 35265820)
118. Kandiah N., Feldman H. H., Therapeutic potential of statins in Alzheimer's disease. Journal of the Neurological Sciences 2009 283 1-2 230 234 2-s2.0-67650128395 10.1016/j.jns.2009.02.352
119. Knopp R. H., Drug treatment of lipid disorders. The New England Journal of Medicine 1999 341 7 498 511 2-s2.0-0033549840 10.1056/NEJM199908123410707 (Pubitemid 29372891)
120. Tsuji A., Saheki A., Tamai I., Terasaki T., Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. Journal of Pharmacology and Experimental Therapeutics 1993 267 3 1085 1090 2-s2.0-0027723663 (Pubitemid 24068669)
121. Uranga R. M., Keller J. N., Diet and age interactions with regards to cholesterol regulation and brain pathogenesis. Current Gerontology and Geriatrics Research 2010 2010 14 2-s2.0-78349287022 10.1155/2010/219683 219683
122. Mailman T., Hariharan M., Karten B., Inhibition of neuronal cholesterol biosynthesis with lovastatin leads to impaired synaptic vesicle release even in the presence of lipoproteins or geranylgeraniol. Journal of Neurochemistry 2011 119 5 1002 1015
123. Patterson M. C., Di Bisceglie A. M., Higgins J. J., Abel R. B., Schiffmann R., Parker C. C., Argoff C. E., Grewal R. P., Yu K., Pentchev P. G., Brady R. O., Barton N. W., The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann-Pick disease type C. Neurology 1993 43 1 61 64 2-s2.0-0027395364 (Pubitemid 23035358)
124. Liu B., Li H., Repa J. J., Turley S. D., Dietschy J. M., Genetic variations and treatments that affect the lifespan of the NPC1 mouse. Journal of Lipid Research 2008 49 3 663 669 2-s2.0-42949148332 10.1194/jlr.M700525-JLR200
125. Bohr I., Hypercholesterolemic diet applied to rat dams protects their offspring against cognitive deficits. Simulated neonatal anoxia model. Physiology and Behavior 2004 82 4 703 711 2-s2.0-4344662399 10.1016/j.physbeh. 2004.06.009 (Pubitemid 39141087)
126. Schreurs B. G., The effects of cholesterol on learning and memory. Neuroscience and Biobehavioral Reviews 2010 34 8 1366 1379 2-s2.0-77954175073 10.1016/j.neubiorev.2010.04.010
127. Whitmer R. A., Sidney S., Selby J., Claiborne Johnston S., Yaffe K., Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005 64 2 277 281 2-s2.0-12744273863
128. Yaffe K., Barrett-Connor E., Lin F., Grady D., Serum lipoprotein levels, statin use, and cognitive function in older women. Archives of Neurology 2002 59 3 378 384 2-s2.0-0036186663 (Pubitemid 34208144)
129. Solomon A., Kåreholt I., Ngandu T., Winblad B., Nissinen A., Tuomilehto J., Soininen H., Kivipelto M., Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 2007 68 10 751 756 2-s2.0-33947500485 10.1212/01.wnl.0000256368.57375.b7 (Pubitemid 46667900)
130. Näslund J., Haroutunian V., Mohs R., Davis K. L., Davies P., Greengard P., Buxbaum J. D., Correlation between elevated levels of amyloid β -peptide in the brain and cognitive decline. Journal of the American Medical Association 2000 283 12 1571 1577 2-s2.0-0038117796 (Pubitemid 30161512)
131. Kivipelto M., Helkala E. L., Hänninen T., Laakso M. P., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., Nissinen A., Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001 56 12 1683 1689 2-s2.0-0035954333 (Pubitemid 32574567)
132. Mielke M. M., Zandi P. P., Sjögren M., Gustafson D., Östling S., Steen B., Skoog I., High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005 64 10 1689 1695 2-s2.0-18844457544 10.1212/01.WNL.0000161870.78572.A5 (Pubitemid 40695799)
133. Perry L. A., Stigger C. B., Ainsworth B. E., Zhang J., No association between cognitive achievements, academic performance and serum cholesterol concentrations among school-aged children. Nutritional Neuroscience 2009 12 4 160 166 2-s2.0-70350445259 10.1179/147683009X423328
134. Muldoon M. F., Ryan C. M., Sereika S. M., Flory J. D., Manuck S. B., Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. American Journal of Medicine 2004 117 11 823 829 2-s2.0-3843148550 10.1016/j.amjmed.2004.07.041 (Pubitemid 39602790)
135. Muldoon M. F., Barger S. D., Ryan C. M., Flory J. D., Lehoczky J. P., Matthews K. A., Manuck S. B., Effects of lovastatin on cognitive function and psychological well-being. American Journal of Medicine 2000 108 7 538 546 2-s2.0-0034015649 10.1016/S0002-9343(00)00353-3 (Pubitemid 30249031)
136. Trompet S., Van Vliet P., De Craen A. J. M., Jolles J., Buckley B. M., Murphy M. B., Ford I., MacFarlane P. W., Sattar N., Packard C. J., Stott D. J., Shepherd J., Bollen E. L. E. M., Blauw G. J., Jukema J. W., Westendorp R. G. J., Pravastatin and cognitive function in the elderly. Results of the PROSPER study. Journal of Neurology 2010 257 1 85 90 2-s2.0-74849094929 10.1007/s00415-009-5271-7
137. FDA, US Food and Drug Administration, FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs 2012., 2012
138. Arvanitakis Z., Schneider J. A., Wilson R. S., Bienias J. L., Kelly J. F., Evans D. A., Bennett D. A., Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 2008 70 19, part 2 1795 1802 2-s2.0-43249094747 10.1212/01.wnl.0000288181.00826.63 (Pubitemid 351653958)
139. Haag M. D. M., Hofman A., Koudstaal P. J., Stricker B. H. C., Breteler M. M. B., Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. Journal of Neurology, Neurosurgery and Psychiatry 2009 80 1 13 17 2-s2.0-58249089520 10.1136/jnnp.2008.150433
140. Rea T. D., Breitner J. C., Psaty B. M., Fitzpatrick A. L., Lopez O. L., Newman A. B., Hazzard W. R., Zandi P. P., Burke G. L., Lyketsos C. G., Bernick C., Kuller L. H., Statin use and the risk of incident dementia: the Cardiovascular Health Study. Archives of Neurology 2005 62 7 1047 1051 2-s2.0-22844431778 10.1001/archneur.62.7.1047 (Pubitemid 41043724)
141. Dong W., Vuletic S., Albers J. J., Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. Journal of Lipid Research 2009 50 10 2095 2102 2-s2.0-70350351085 10.1194/jlr.M900236-JLR200
142. Cole S. L., Grudzien A., Manhart I. O., Kelly B. L., Oakley H., Vassar R., Statins cause intracellular accumulation of amyloid precursor protein, β -secretase-cleaved fragments, and amyloid β -peptide via an isoprenoid-dependent mechanism. The Journal of Biological Chemistry 2005 280 19 18755 18770 2-s2.0-21444445440 10.1074/jbc.M413895200 (Pubitemid 41379577)
143. Lu F., Li X., Suo A. Q., Zhang J. W., Inhibition of tau hyperphosphorylation and beta amyloid production in rat brain by oral administration of atorvastatin. Chinese Medical Journal 2010 123 14 1864 1870 2-s2.0-78649537359 10.3760/cma.j.issn.0366-6999.2010.14.007
144. Kurata T., Miyazaki K., Kozuki M., Panin V. L., Morimoto N., Ohta Y., Nagai M., Ikeda Y., Matsuura T., Abe K., Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Research 2011 1371 C 161 170 2-s2.0-78651365099 10.1016/j.brainres. 2010.11.067
145. Serrano-Pozo A., Vega G. L., Lütjohann D., Locascio J. J., Tennis M. K., Deng A., Atri A., Hyman B. T., Irizarry M. C., Growdon J. H., Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Disease and Associated Disorders 2010 24 3 220 226 2-s2.0-77956411745 10.1097/WAD.0b013e3181d61fea
146. Feldman H. H., Doody R. S., Kivipelto M., Sparks D. L., Waters D. D., Jones R. W., Schwam E., Schindler R., Hey-Hadavi J., Demicco D. A., Breazna A., Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010 74 12 956 964 2-s2.0-77949908687 10.1212/WNL.0b013e3181d6476a
147. Sato N., Shinohara M., Rakugi H., Dual effects of statins on Abeta metabolism: upregulation of the degradation of APP-CTF and Abeta clearance. Neurodegenerative Diseases 2012 10 14 305 308
148. Elkind M. S. V., Flint A. C., Sciacca R. R., Sacco R. L., Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology 2005 65 2 253 258 2-s2.0-22544457919 10.1212/01.WNL.0000171746.63844. 6a (Pubitemid 41022370)
149. Blanco M., Nombela F., Castellanos M., Rodriguez-Yáñez M., García-Gil M., Leira R., Lizasoain I., Serena J., Vivancos J., Moro M. A., Dávalos A., Castillo J., Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007 69 9 904 910 2-s2.0-34548278923 10.1212/01.wnl.0000269789.09277.47 (Pubitemid 47329591)
150. Elkind M. S. V., Sacco R. L., Macarthur R. B., Fink D. J., Peerschke E., Andrews H., Neils G., Stillman J., Corporan T., Leifer D., Cheung K., The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. International Journal of Stroke 2008 3 3 210 218 2-s2.0-48849116060 10.1111/j.1747-4949.2008.00200.x
151. Cui J. J., Wang D., Gao F., Effects of atorvastatin on pathological changes in brain tissue and plasma MMP-9 in rats with intracerebral hemorrhage. Cell Biochemistry and Biophysics 2012 62 1 87 90
152. Ignatius M. J., Gebicke-Harter P. J., Skene J. H. P., Expression of apolipoprotein E during nerve degeneration and regeneration. Proceedings of the National Academy of Sciences of the United States of America 1986 83 4 1125 1129 2-s2.0-0012796286 (Pubitemid 16086425)
153. Pitas R. E., Boyles J. K., Lee S. H., Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochimica et Biophysica Acta 1987 917 1 148 161 2-s2.0-0023080585 (Pubitemid 17231059)
154. Evans B. A., Evans J. E., Baker S. P., Kane K., Swearer J., Hinerfeld D., Caselli R., Rogaeva E., George -. P. S., Moonis M., Pollen D. A., Long-term statin therapy and CSF cholesterol levels: implications for alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2009 27 6 519 524 2-s2.0-66149141822 10.1159/000221835
155. Von Eckardstein A., Huang Y., Kastelein J. J. P., Geisel J., Real J. T., Kuivenhoven J. A., Miccoli R., Noseda G., Assmann G., Lipid-free apolipoprotein (apo) A-I is converted into alpha-migrating high density lipoproteins by lipoprotein-depleted plasma of normolipidemic donors and apo A-I-deficient patients but not of Tangier disease patients. Atherosclerosis 1998 138 1 25 34 2-s2.0-17744414890 10.1016/S0021-9150(97)00280-3 (Pubitemid 28255151)
156. Bellosta S., Nathan B. P., Orth M., Dong L. M., Mahley R. W., Pitas R. E., Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. The Journal of Biological Chemistry 1995 270 45 27063 27071 2-s2.0-0028850374 10.1074/jbc.270.45.27063
157. LaDu M. J., Gilligan S. M., Lukens J. R., Cabana V. G., Reardon C. A., Van Eldik L. J., Holtzman D. M., Nascent astrocyte particles differ from lipoproteins in CSF. Journal of Neurochemistry 1998 70 5 2070 2081 2-s2.0-0031970198 (Pubitemid 28207831)
158. Buttini M., Orth M., Bellosta S., Akeefe H., Pitas R. E., Wyss-Coray T., Mucke L., Mahley R. W., Expression of human apolipoprotein E3 or E4 in the brains of Apoe(-/-) mice: isoform-specific effects on neurodegeneration. Journal of Neuroscience 1999 19 12 4867 4880 2-s2.0-0033564771 (Pubitemid 29270123)
159. Pottier C., Hannequin D., Coutant S., High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Molecular Psychiatry 2012 17 9 875 879
160. Ignatius M. J., Shooter E. M., Pitas R. E., Mahley R. W., Lipoprotein uptake by neuronal growth cones in vitro. Science 1987 236 4804 950 962 2-s2.0-0023662285 (Pubitemid 17107946)
161. Spoelgen R., Hammes A., Anzenberger U., Zechner D., Andersen O. M., Jerchow B., Willnow T. E., LRP2/megalin is required for patterning of the ventral telencephalon. Development 2005 132 2 405 414 2-s2.0-13944258550 10.1242/dev.01580 (Pubitemid 40268289)
162. Hack I., Hellwig S., Junghans D., Brunne B., Bock H. H., Zhao S., Frotscher M., Divergent roles of ApoER2 and Vldlr in the migration of cortical neurons. Development 2007 134 21 3883 3891 2-s2.0-36549059188 10.1242/dev.005447 (Pubitemid 350187347)
163. Herz J., Chen Y., Reelin, lipoprotein receptors and synaptic plasticity. Nature Reviews Neuroscience 2006 7 11 850 859 2-s2.0-33750333569 10.1038/nrn2009 (Pubitemid 44624177)
164. Durakoglugil M. S., Chen Y., White C. L., Kavalali E. T., Herz J., Reelin signaling antagonizes β -amyloid at the synapse. Proceedings of the National Academy of Sciences of the United States of America 2009 106 37 15938 15943 2-s2.0-70349452303 10.1073/pnas.0908176106
165. Witzlack T., Wenzeck T., Thiery J., Orth M., cAMP-induced expression of ABCA1 is associated with MAP-kinase-pathway activation. Biochemical and Biophysical Research Communications 2007 363 1 89 94 2-s2.0-34548774467 10.1016/j.bbrc.2007.08.109 (Pubitemid 47430098)
166. Larouche M., Beffert U., Herz J., Hawkes R., The reelin receptors Apoer2 and Vldlr coordinate the patterning of purkinje cell topography in the developing mouse cerebellum. PLoS ONE 2008 3 2 2-s2.0-45749090990 10.1371/journal.pone.0001653 e1653 (Pubitemid 351865655)
167. Zong Y., Zhang B., Gu S., Structural basis of agrin-LRP4-MuSK signaling. Genes & Development 2012 26 3 247 258
168. Kantarci S., Al-Gazali L., Hill R. S., Donnai D., Black G. C. M., Bieth E., Chassaing N., Lacombe D., Devriendt K., Teebi A., Loscertales M., Robson C., Liu T., MacLaughlin D. T., Noonan K. M., Russell M. K., Walsh C. A., Donahoe P. K., Pober B. R., Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nature Genetics 2007 39 8 957 959 2-s2.0-34547549299 10.1038/ng2063 (Pubitemid 47185171)
169. Boycott K. M., Bonnemann C., Herz J., Neuert S., Beaulieu C., Scott J. N., Venkatasubramanian A., Parboosingh J. S., Mutations in VLDLR as a cause for autosomal recessive cerebellar ataxia with mental retardation (Dysequilibrium syndrome). Journal of Child Neurology 2009 24 10 1310 1315 2-s2.0-74949091198 10.1177/0883073809332696
170. Boycott K. M., Flavelle S., Bureau A., Glass H. C., Fujiwara T. M., Wirrell E., Davey K., Chudley A. E., Scott J. N., McLeod D. R., Parboosingh J. S., Homozygous deletion of the very low density lipoprotein receptor gene causes autosomal recessive cerebellar hypoplasia with cerebral gyral simplification. American Journal of Human Genetics 2005 77 3 477 483 2-s2.0-23944470349 10.1086/444400 (Pubitemid 41192653)
171. Ozcelik T., Akarsu N., Uz E., Caglayan S., Gulsuner S., Onat O. E., Tan M., Tan U., Mutations in the very low-density lipoprotein receptor VLDLR cause cerebellar hypoplasia and quadrupedal locomotion in humans. Proceedings of the National Academy of Sciences of the United States of America 2008 105 11 4232 4236 2-s2.0-41949138166 10.1073/pnas.0710010105 (Pubitemid 351754363)
172. Park T. J., Curran T., Crk and Crk-like play essential overlapping roles downstream of disabled-1 in the reelin pathway. Journal of Neuroscience 2008 28 50 13551 13562 2-s2.0-58149379046 10.1523/JNEUROSCI.4323-08.2008
173. Handelmann G. E., Boyles J. K., Weisgraber K. H., Mahley R. W., Pitas R. E., Effects of apolipoprotein E, β -very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. Journal of Lipid Research 1992 33 11 1677 1688 2-s2.0-0026443801
174. Orth M., Weng W., Funke H., Steinmetz A., Assmann G., Nauck M., Dierkes J., Ambrosch A., Weisgraber K. H., Mahley R. W., Wieland H., Luley C., Effects of a frequent apolipoprotein E isoform, apoE4(Freiburg) (Leu28→Pro), on lipoproteins and the prevalence of coronary artery disease in Whites. Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 5 1306 1315 2-s2.0-0032912218 (Pubitemid 29227652)
175. Mahley R. W., Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988 240 4852 622 630 2-s2.0-0024299370
176. Lahiri D. K., Apolipoprotein E as a target for developing new therapeutics for Alzheimer's disease based on studies from protein, RNA, and regulatory region of the gene. Journal of Molecular Neuroscience 2004 23 3 225 233 2-s2.0-4143097904
177. Linton M. F., Gish R., Hubl S. T., Butler E., Esquivel C., Bry W. I., Boyles J. K., Wardell M. R., Young S. G., Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. Journal of Clinical Investigation 1991 88 1 270 281 2-s2.0-0025878638
178. Mahley R. W., Weisgraber K. H., Huang Y., Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2006 103 15 5644 5651 2-s2.0-33645808672 10.1073/pnas.0600549103
179. Pu-Ting X., Gilbert J. R., Hui-Ling Q., Ervin J., Rothrock-Christian T. R., Hulette C., Schmechel D. E., Specific regional transcription of apolipoprotein E in human brain neurons. American Journal of Pathology 1999 154 2 601 611 2-s2.0-0344267650 (Pubitemid 29094109)
180. Wahrle S. E., Jiang H., Parsadanian M., Legleiter J., Han X., Fryer J. D., Kowalewski T., Holtzman D. M., ABCA1 is required for normal central nervous system apoE levels and for lipidation of astrocyte-secreted apoE. The Journal of Biological Chemistry 2004 279 39 40987 40993 2-s2.0-4644361588 10.1074/jbc.M407963200 (Pubitemid 39287699)
181. Hirsch-Reinshagen V., Maia L. F., Burgess B. L., Blain J. F., Naus K. E., McIsaac S. A., Parkinson P. F., Chan J. Y., Tansley G. H., Hayden M. R., Poirier J., Van Nostrand W., Wellington C. L., The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. The Journal of Biological Chemistry 2005 280 52 43243 43256 2-s2.0-30044441879 10.1074/jbc.M508781200 (Pubitemid 43049291)
182. Liu Q., Zerbinatti C. V., Zhang J., Hoe H. S., Wang B., Cole S. L., Herz J., Muglia L., Bu G., Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 2007 56 1 66 78 2-s2.0-34748897213 10.1016/j.neuron.2007.08.008 (Pubitemid 47484175)
183. Anderson R., Barnes J. C., Bliss T. V. P., Cain D. P., Cambon K., Davies H. A., Errington M. L., Fellows L. A., Gray R. A., Hoh T., Stewart M., Large C. H., Higgins G. A., Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse. Neuroscience 1998 85 1 93 110 2-s2.0-0031971420 10.1016/S0306-4522(97)00598-8 (Pubitemid 28228418)
184. Fagan A. M., Murphy B. A., Patel S. N., Kilbridge J. F., Mobley W. C., Bu G., Holtzman D. M., Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (-/-) mice but impaired clearance of axonal degeneration products following injury. Experimental Neurology 1998 151 2 314 325 2-s2.0-0032101868 10.1006/exnr.1998.6818 (Pubitemid 28285911)
185. Holtzman D. M., Herz J., Bu G., Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2012 2 3 a006312
186. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993 261 5123 921 923 2-s2.0-0027194791 (Pubitemid 23275809)
187. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., Roses A. D., Apolipoprotein E: high-avidity binding to β -amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1993 90 5 1977 1981 2-s2.0-0027407565 (Pubitemid 23069980)
188. Schmechel D. E., Saunders A. M., Strittmatter W. J., Crain B. J., Hulette C. M., Joo S. H., Pericak-Vance M. A., Goldgaber D., Roses A. D., Increased amyloid β -peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1993 90 20 9649 9653 2-s2.0-0027365822 10.1073/pnas.90.20.9649 (Pubitemid 23315843)
189. Ward A., Crean S., Mercaldi C. J., Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. Neuroepidemiology 2012 38 1 1 17
190. Blacker D., Haines J. L., Rodes L., Terwedow H., Go R. C. P., Harrell L. E., Perry R. T., Bassett S. S., Chase G., Meyers D., Albert M. S., Tanzi R., ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology 1997 48 1 139 147 2-s2.0-17744410836 (Pubitemid 27039532)
191. Strittmatter W. J., Medicine. Old drug, new hope for Alzheimer's disease. Science 2012 335 6075 1447 1448
192. Hatters D. M., Peters-Libeu C. A., Weisgraber K. H., Apolipoprotein E structure: insights into function. Trends in Biochemical Sciences 2006 31 8 445 454 2-s2.0-33746311471 10.1016/j.tibs.2006.06.008 (Pubitemid 44108662)
193. Ramaswamy G., Xu Q., Huang Y., Weisgraber K. H., Effect of domain interaction on apolipoprotein E levels in mouse brain. Journal of Neuroscience 2005 25 46 10658 10663 2-s2.0-27944466636 10.1523/JNEUROSCI.1922-05.2005 (Pubitemid 41681913)
194. Zhong N., Weisgraber K. H., Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. The Journal of Biological Chemistry 2009 284 10 6027 6031 2-s2.0-65249158083 10.1074/jbc.R800009200
195. Dunker A. K., Oldfield C. J., Meng J., Romero P., Yang J. Y., Chen J. W., Vacic V., Obradovic Z., Uversky V. N., The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics 2008 9 supplement 2 S1 2-s2.0-52249085709 10.1186/1471-2164-9-S2-S1
196. Sanan D. A., Weisgraber K. H., Russell S. J., Mahley R. W., Huang D., Saunders A., Schmechel D., Wisniewski T., Frangione B., Roses A. D., Strittmatter W. J., Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform ApoE4 associates more efficiently than ApoE3. Journal of Clinical Investigation 1994 94 2 860 869 2-s2.0-0028026587
197. LaDu M. J., Falduto M. T., Manelli A. M., Reardon C. A., Getz G. S., Frail D. E., Isoform-specific binding of apolipoprotein E to β -amyloid. The Journal of Biological Chemistry 1994 269 38 23403 23406 2-s2.0-0027931854
198. Aleshkov S., Abraham C. R., Zannis V. I., Interaction of nascent apoe2, apoe3, and apoe4 isoforms expressed in mammalian cells with amyloid peptide β (1-40). Relevance to Alzheimer's disease. Biochemistry 1997 36 34 10571 10580 2-s2.0-0030867936 10.1021/bi9626362 (Pubitemid 27374151)
199. Jiang Q., Lee C. Y. D., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Willson T. M., Collins J. L., Richardson J. C., Smith J. D., Comery T. A., Riddell D., Holtzman D. M., Tontonoz P., Landreth G. E., ApoE promotes the proteolytic degradation of A β Neuron 2008 58 5 681 693 2-s2.0-44649197748 10.1016/j.neuron.2008.04.010 (Pubitemid 351778466)
200. DeMattos R. B., Cirrito J. R., Parsadanian M., May P. C., O'Dell M. A., Taylor J. W., Harmony J. A. K., Aronow B. J., Bales K. R., Paul S. M., Holtzman D. M., ApoE and clusterin cooperatively suppress A β levels and deposition: evidence that ApoE regulates extracellular A β metabolism in vivo. Neuron 2004 41 2 193 202 2-s2.0-9144224765 10.1016/S0896-6273(03)00850-X (Pubitemid 38125181)
201. Bell R. D., Sagare A. P., Friedman A. E., Bedi G. S., Holtzman D. M., Deane R., Zlokovic B. V., Transport pathways for clearance of human Alzheimer's amyloid β -peptide and apolipoproteins E and J in the mouse central nervous system. Journal of Cerebral Blood Flow and Metabolism 2007 27 5 909 918 2-s2.0-34247506244 10.1038/sj.jcbfm.9600419 (Pubitemid 46659038)
202. Zlokovic B. V., The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008 57 2 178 201 2-s2.0-38149090292 10.1016/j.neuron.2008.01.003
203. Frieden C., Garai K., Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2012 109 23 8913 8918
204. Peters-Libeu C. A., Newhouse Y., Hatters D. M., Weisgraber K. H., Model of biologically active apolipoprotein E bound to dipalmitoylphosphatidylcholine. The Journal of Biological Chemistry 2006 281 2 1073 1079 2-s2.0-33644861785 10.1074/jbc.M510851200
205. Wilson C., Wardell M. R., Weisgraber K. H., Mahley R. W., Agard D. A., Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 1991 252 5014 1817 1822 2-s2.0-0025860481 (Pubitemid 21917100)
206. Sivashanmugan A., Wang J., A unified scheme for initiation and conformational adaptation of human apolipoprotein E N-terminal domain upon lipoprotein binding and for receptor binding activity. The Journal of Biological Chemistry 2009 284 21 14657 14666 2-s2.0-67649785032 10.1074/jbc.M901012200
207. Chen H. K., Ji Z. S., Dodson S. E., Miranda R. D., Rosenblum C. I., Reynolds I. J., Freedman S. B., Weisgraber K. H., Huang Y., Mahley R. W., Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for alzheimer disease. The Journal of Biological Chemistry 2011 286 7 5215 5221 2-s2.0-79953130715 10.1074/jbc.M110.151084
208. Bell R. D., Winkler E. A., Singh I., Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012 485 7399 512 516
209. Cramer P. E., Cirrito J. R., Wesson D. W., ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012 335 6075 1503 1506
210. Vitek M. P., Christensen D. J., Wilcock D., APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer's disease transgenics. Neurodegenerative Diseases 2012 10 14 122 126
211. Lynch J. R., Tang W., Wang H., Vitek M. P., Bennett E. R., Sullivan P. M., Warner D. S., Laskowitz D. T., APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. The Journal of Biological Chemistry 2003 278 49 48529 48533 2-s2.0-1542467336 10.1074/jbc.M306923200 (Pubitemid 41079490)
212. Nuutinen T., Suuronen T., Kauppinen A., Salminen A., Clusterin: a forgotten player in Alzheimer's disease. Brain Research Reviews 2009 61 2 89 104 2-s2.0-70349557788 10.1016/j.brainresrev.2009.05.007
213. Charnay Y., Imhof A., Vallet P. G., Hakkoum D., Lathuiliere A., Poku N., Aronow B., Kovari E., Bouras C., Giannakopoulos P., Clusterin expression during fetal and postnatal CNS development in mouse. Neuroscience 2008 155 3 714 724 2-s2.0-49449107317 10.1016/j.neuroscience.2008.06.022
214. Iwata A., Browne K. D., Chen X. H., Yuguchi T., Smith D. H., Traumatic brain injury induces biphasic upregulation of ApoE and ApoJ protein in rats. Journal of Neuroscience Research 2005 82 1 103 114 2-s2.0-27744495001 10.1002/jnr.20607 (Pubitemid 41604802)
215. De Silva H. V., Harmony J. A. K., Stuart W. D., Gil C. M., Robbins J., Apolipoprotein J: structure and tissue distribution. Biochemistry 1990 29 22 5380 5389 2-s2.0-0025301469 10.1021/bi00474a025 (Pubitemid 20193947)
216. Bailey R. W., Dunker A. K., Brown C. J., Garner E. C., Griswold M. D., Clusterin, a binding protein with a molten globule-like region. Biochemistry 2001 40 39 11828 11840 2-s2.0-0035797917 10.1021/bi010135x (Pubitemid 32906044)
217. Cole G. M., Ard M. D., Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein. Microscopy Research and Technique 2000 50 4 316 324 (Pubitemid 30651172)
218. Shibata M., Yamada S., Ram Kumar S., Calero M., Bading J., Frangione B., Holtzman D. M., Miller C. A., Strickland D. K., Ghiso J., Zlokovic B. V., Clearance of Alzheimer's amyloid- β 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. Journal of Clinical Investigation 2000 106 12 1489 1499 2-s2.0-0034521392 (Pubitemid 32038587)
219. Bell R. D., Deane R., Chow N., Long X., Sagare A., Singh I., Streb J. W., Guo H., Rubio A., Van Nostrand W., Miano J. M., Zlokovic B. V., SRF and myocardin regulate LRP-mediated amyloid- β clearance in brain vascular cells. Nature Cell Biology 2009 11 2 143 153 2-s2.0-59649110562 10.1038/ncb1819
220. Lütjohann D., Meichsner S., Pettersson H., Lipids in Alzheimer's disease and their potential for therapy. Journal of Clinical Lipidology 2012 7 1 65 78
221. Popp J., Lewczuk P., Kölsch H., Meichsner S., Maier W., Kornhuber J., Jessen F., Lütjohann D., Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. Journal of Neurochemistry 2012 123 2 310 316 2-s2.0-84867091169 10.1111/j.1471-4159.2012. 07893.x
222. Ye S., Huang Y., Müllendorff K., Dong L., Giedt G., Meng E. C., Cohen F. E., Kuntz I. D., Weisgraber K. H., Mahley R. W., Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America 2005 102 51 18700 18705 2-s2.0-29444460533 10.1073/pnas.0508693102 (Pubitemid 43011289)
223. Marks N., Berg M. J., BACE and γ -secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis. Neurochemical Research 2010 35 2 181 210 2-s2.0-76849098161 10.1007/s11064-009-0054-1
224. Hoe H. S., Wessner D., Beffert U., Becker A. G., Matsuoka Y., Rebeck G. W., F-spondin interaction with the apolipoprotein E receptor ApoEr2 affects processing of amyloid precursor protein. Molecular and Cellular Biology 2005 25 21 9259 9268 2-s2.0-27144504391 10.1128/MCB.25.21.9259-9268.2005 (Pubitemid 41507828)
225. Rietveld A., Simons K., The differential miscibility of lipids as the basis for the formation of functional membrane rafts. Biochimica et Biophysica Acta 1998 1376 3 467 479 2-s2.0-0031740079 10.1016/S0304-4157(98)00019-7 (Pubitemid 28517893)
226. Koistinaho M., Lin S., Wu X., Esterman M., Koger D., Hanson J., Higgs R., Liu F., Malkani S., Bales K. R., Paul S. M., Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid- β peptides. Nature Medicine 2004 10 7 719 726 2-s2.0-3142781310 10.1038/nm1058 (Pubitemid 38937637)
227. El Khoury J., Luster A. D., Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends in Pharmacological Sciences 2008 29 12 626 632 2-s2.0-56349166514 10.1016/j.tips.2008.08.004
228. Billings L. M., Oddo S., Green K. N., McGaugh J. L., LaFerla F. M., Intraneuronal A β causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005 45 5 675 688 2-s2.0-14644442872 10.1016/j.neuron.2005.01.040 (Pubitemid 40320703)
229. Bales K. R., Verina T., Dodel R. C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E. M., Little S. P., Cummins D. J., Piccardo P., Ghetti B., Paul S. M., Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nature genetics 1997 17 3 263 264 2-s2.0-0031278270
230. Abad-Rodriguez J., Ledesma M. D., Craessaerts K., Perga S., Medina M., Delacourte A., Dingwall C., De Strooper B., Dotti C. G., Neuronal membrane cholesterol loss enhances amyloid peptide generation. Journal of Cell Biology 2004 167 5 953 960 2-s2.0-10344263931 10.1083/jcb.200404149 (Pubitemid 39628117)
231. Kaether C., Haass C., A lipid boundary separates APP and secretases and limits amyloid β -peptide generation. Journal of Cell Biology 2004 167 5 809 812 2-s2.0-10344226187 10.1083/jcb.200410090 (Pubitemid 39628103)
232. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C. G., Simons K., Cholesterol depletion inhibits the generation of β -amyloid in hippocampal neurons. Proceedings of the National Academy of Sciences of the United States of America 1998 95 11 6460 6464 2-s2.0-0032568552 10.1073/pnas.95.11.6460 (Pubitemid 28249035)
233. Ehehalt R., Keller P., Haass C., Thiele C., Simons K., Amyloidogenic processing of the Alzheimer β -amyloid precursor protein depends on lipid rafts. Journal of Cell Biology 2003 160 1 113 123 2-s2.0-0037421206 10.1083/jcb.200207113 (Pubitemid 36091721)